Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M
June 30, 2022
Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M to further advance breakthrough auto-immune disease therapeutics.
Formation of a Scientific Advisory Board
February 3, 2022
Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs pharmacology, immunology, drug discovery and development for auto-immune diseases
Ermium Therapeutics at the Biotech Showcase
January 10, 2022
Ermium Therapeutics is a presenting company at the Biotech Showcase, investor conference for innovators.Ermium Therapeutics at BIO-Europe Fall 2021
October 25, 2021
Ermium Therapeutics is participating to BIO-Europe Fall 2021 meeting and its partnering sessionsErmium Therapeutics achieves breakthrough R&D progress with its proprietary CXCR4-targeted functionally selective immunomodulator
October 15, 2021
Besides the already published in vitro and vivo proof of concept data, Ermium established, with a proprietary CXCR4-targeted non antagonist immunomodulator, proof of concept in three in vivo models, including in a well-known murine disease model of systemic lupus erythematosus.Ermium Therapeutics at Bio€quity Europe
May 17, 2021
Ermium Therapeutics is a presenting company at Bio€quity Europe and is participating to the partnering meetingsKristof Van Emelen, PhD, joins Ermium Therapeutics as Head of Medicinal Chemistry
April 1, 2021
Ermium Therapeutics is strengthening its management team with the appointment of Kristof Van Emelen as Head of Medicinal Chemistry.Annegret Van der Aa, PhD joins Ermium Therapeutics
March 8, 2021
Ermium Therapeutics strengthen its leadership team with the appointment of Annegret Van der Aa as CSO/CDO.
Laurent Audoly, PhD, President and CEO of Parthenon Therapeutics, as non executive director of Ermium Therapeutics
January 9, 2021
Laurent Audoly is a pharma and biotech entrepreneur and senior executive. He is co-founder, CEO and Chairman of Parthenon Therapeutics, and has also led corporate and R&D functions across both pharma and biotech in the US and Europe, particularly in the field of auto-immune diseases, including as CEO of Kymera Therapeutics and Head of R&D at Pierre Fabre Pharmaceuticals, as well as scientific and business leadership positions at Pfizer, Merck and Pieris. Ermium integrates the Cochin Paris Santé incubator
October 19, 2020
Ermium Therapeutics is settling its laboratories and offices at the Cochin Paris Santé incubator, the 1rst French incubator dedicated to innovative start-ups in the healthcare field, located within the Paris Cochin Hospital.